Signal A global pharma company simulates enrollment and diversity targets on a clinical-trial digital twin

Summary

NTT DATA's pharmaceutical use case describes an unnamed global drug company that builds a digital twin of its clinical trials. The twin brings together protocol design, historical trial data, real-world evidence and the performance of trial sites. Before the first patient is enrolled, teams use it to simulate enrollment curves, diversity targets, site risk and likely protocol deviations. Trusted AI models validated with full lineage then keep updating the twin as real-world data arrives. They recommend actions such as switching on backup sites or adjusting visit schedules. Expected results include faster database lock, better diversity, fewer amendments, stronger inspection readiness and full transparency for regulators and partners.